Barrington Research Reiterates Integra LifeSciences Outperform, $50 PT
Barrington Research reiterated its Integra LifeSciences (NASDAQ: IART) Outperform rating and $50 price target in a research report published today.
In the report, Barrington Research states, "We are reiterating our OUTPERFORM rating and $50 target following IART's Q4/11 results based on the organic and inorganic growth opportunities in each of IART's end markets."
Shares of Integra LifeSciences were trading at $31.77 at the time of posting, up 1.92% from Monday's market close.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.